Lantern Pharma Q3 net loss $4.05M, cash $73.8M; RADR hits 10B datapoints, LP-184 ODD

Lantern Pharma Inc.

Net loss $4.05M ($0.36 per share) vs $1.70M in Q3 2020; R&D expenses $2.96M up from $0.60M.
Cash and marketable securities $73.8M as of Sep 30, 2021, up from $19.2M at Dec 31, 2020.
RADR platform surpassed 10 billion curated oncology data points, up from 4.6B in earlier 2021.
LP-184 received Orphan Drug Designation from FDA for pancreatic cancer and glioblastoma.
Announced strategic collaborations with Deep Lens and Code Ocean; planning Phase 2 trial for LP-300.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.